Erectile Dysfunction: Evaluation and Treatment
First-Line Treatment
Start with a PDE5 inhibitor (sildenafil, vardenafil, tadalafil, or avanafil) in all men seeking treatment for erectile dysfunction who do not have contraindications—this is the most effective initial therapy with strong evidence for improving sexual function and quality of life 1.
The choice among PDE5 inhibitors should be based on patient preference regarding onset time, duration of action, and cost, as head-to-head comparisons show no significant efficacy differences 1. All four agents demonstrate clinically meaningful improvements in erectile function regardless of underlying cause (diabetes, cardiovascular disease, post-prostatectomy) or baseline severity 1.
Key Contraindications and Cautions
- Absolute contraindication: Concurrent nitrate therapy (risk of severe hypotension) 1
- Higher doses of sildenafil and vardenafil provide modestly greater benefit but increase adverse event risk 1
- Adverse events are typically mild to moderate (headache, flushing, dyspepsia) and similar across all PDE5 inhibitors 1
Initial Evaluation
Essential History Elements
Focus on:
- Duration of symptoms (≥3 months warrants evaluation) 1
- Cardiovascular risk factors: diabetes, hypertension, hyperlipidemia, smoking, obesity 2, 3, 4, 5
- Medication review: antidepressants and tobacco are common culprits 5
- Psychosexual factors: performance anxiety, relationship issues, depression 3, 4
- Surgical history: pelvic/perineal trauma, prostate cancer treatment 2, 4
- Symptoms suggesting hypogonadism: decreased libido, fatigue, testicular/muscle atrophy 1
Required Laboratory Tests
The 2025 EAU guidelines specify 2:
- Fasting glucose and lipid profile (cardiovascular risk assessment)
- Morning total testosterone (if not assessed in last 12 months)
- Consider bioavailable or free testosterone if total testosterone is borderline
Important caveat: Routine hormonal testing remains controversial. The American College of Physicians found insufficient evidence to recommend for or against routine testosterone testing 1. However, the more recent 2025 EAU guidelines recommend morning testosterone as part of standard evaluation 2, reflecting evolving practice patterns. Test testosterone selectively based on clinical presentation (low libido, fatigue, physical signs of hypogonadism) rather than routinely in all men with ED 1.
Management Algorithm
Step 1: Lifestyle Modification (All Patients)
- Tobacco cessation
- Regular exercise and weight loss
- Optimize control of diabetes, hypertension, and hyperlipidemia
- Address relationship issues and performance anxiety 4, 5
Critical point: ED is a sentinel marker for cardiovascular disease—nearly 80% of men with arterial ED have coronary lesions, often appearing 5 years before myocardial infarction or stroke 6. Aggressive cardiovascular risk factor management is essential.
Step 2: PDE5 Inhibitor Trial
Start with any PDE5 inhibitor based on patient preference 1:
- Sildenafil: 50-100 mg, taken 1 hour before intercourse
- Vardenafil: 10-20 mg, taken 1 hour before intercourse
- Tadalafil: 10-20 mg (on-demand) or 2.5-5 mg daily; longer duration of action
- Avanafil: 100-200 mg, fastest onset
Step 3: PDE5 Inhibitor Non-Responders
Before abandoning PDE5 inhibitors, verify proper use 2:
- Confirm correct dosing and timing relative to sexual activity
- Ensure adequate sexual stimulation
- Consider switching to a different PDE5 inhibitor (limited evidence but reasonable) 2
For hypogonadal non-responders: Add testosterone therapy (intramuscular, transdermal, or oral) to PDE5 inhibitor, which may restore effectiveness 2, 1. Testosterone alone shows inconsistent results even in hypogonadal men 1, but combination therapy with PDE5 inhibitors demonstrates benefit 2.
Step 4: Second-Line Therapies
- Intracavernosal injection therapy (alprostadil, papaverine, phentolamine combinations): Effective at any treatment stage with 60-65% success rates 2, 7
- Vacuum erection devices: 90% initial effectiveness 2
- Topical/intraurethral alprostadil: Less effective than injections 2
- Psychosexual counseling: Particularly for psychogenic ED or as adjunct to medical therapy 2, 5
Step 5: Emerging and Investigational Therapies
- Low-intensity shockwave therapy (LI-SWT): May benefit mild vasculogenic ED and PDE5 inhibitor non-responders, especially when combined with daily tadalafil or VED 2. Current EAU recommendation is weak.
- Botulinum toxin A: Shows promise in PDE5 inhibitor non-responders with up to 40% resuming satisfactory sexual activity 2
- Platelet-rich plasma and stem cell therapy: Remain investigational pending efficacy data 2, 7
Step 6: Surgical Options
- Penile prosthesis implantation: Gold standard for refractory ED with high satisfaction rates and low complication rates 2, 3, 7, 4
- Revascularization surgery: Only for young patients with posttraumatic arterial ED; poor outcomes in atherosclerotic disease 2, 4
Special Diagnostic Testing Indications
Advanced testing is not routine but indicated for 2:
- Primary ED (congenital, not acquired)
- Young patients with pelvic/perineal trauma (surgical candidates)
- Penile deformities requiring correction (Peyronie's disease)
- Complex psychiatric/psychosexual disorders
- Complex endocrine disorders
- Medicolegal documentation
Tests include nocturnal penile tumescence, penile duplex ultrasonography with intracavernosal injection, cavernosometry, arteriography, and specialized endocrine/psychiatric evaluation 2.
Common Pitfalls
Failing to assess cardiovascular risk: ED often precedes coronary events by years—aggressive risk factor modification is mandatory 6, 5
Routine testosterone testing without clinical indication: Test selectively based on symptoms (low libido, fatigue) and signs (testicular atrophy), not reflexively 1
Abandoning PDE5 inhibitors prematurely: Verify proper dosing, timing, and sexual stimulation before declaring treatment failure 2
Using testosterone monotherapy in hypogonadal men with ED: Testosterone alone shows inconsistent erectile benefits; combine with PDE5 inhibitors 2, 1
Overlooking psychosocial factors: Even organic ED benefits from addressing performance anxiety and relationship dynamics 2, 5